Gang Chen1, Nino E Giambrone, Philip Lazarus. 1. Departments of Public Health Sciences, Penn State University College of Medicine, Hershey, Pennsylvania 17033, USA.
Abstract
OBJECTIVES: Trans-3'-Hydroxycotinine (3HC) and its glucuronide are major nicotine metabolites excreted in the urine of smokers and other tobacco users. Although several members of the UDP-glucuronosyltransferase (UGT) family of enzymes were previously shown to be active in catalyzing the formation of 3HC and its glucuronide, a comprehensive screening of all known human UGT1A and 2B enzymes for glucuronidation activity against 3HC was not previously performed. METHODS: In the present study, human liver microsomes (HLM), eight UGT1A and six UGT2B enzymes were screened for activity against 3HC. RESULTS: UGT2B17 exhibited the highest O-glucuronidation activity, exhibiting a four-fold lower (P<0.005) KM (8.3 mmol/l) compared with that observed for UGTs 1A9 (35 mmol/l) or 2B7 (31 mmol/l) and a KM smaller compared with that observed for human liver microsomes (HLM; 26 mmol/l). The KM for 3HC-O-Gluc formation was 3.1-fold lower (P<0.0005) in HLM from male participants exhibiting the wild-type genotype UGT2B17 (*1/*1) compared with that in HLM from participants homozygous for the UGT2B17 deletion genotype [UGT2B17 (*2/*2)]. Both UGTs 2B10 and 1A4 exhibited 3HC-N-Gluc formation activity, with UGT2B10 exhibiting a four-fold lower (P<0.05) KM (13 mmol/l) compared with that observed for UGT1A4 (57 mmol/l) and, which was similar to the KM observed in HLM (14 mmol/l). There was 91 (P<0.0001) and 39% (P<0.001) decreases in the 3HC-N-Gluc formation activities in HLM from participants with the UGT2B10 (*2/*2) and UGT2B10 (*1/*2) genotypes, respectively, compared with that of HLM from participants with the wild-type UGT2B10 (*1/*1) genotype. CONCLUSION: These results suggest that UGT2B17 and UGT2B10 play key roles in the glucuronidation of 3HC in the human liver and that functional polymorphisms in UGT2B17 and UGT2B10 are associated with significantly reduced glucuronidation activities against 3HC.
OBJECTIVES:Trans-3'-Hydroxycotinine (3HC) and its glucuronide are major nicotine metabolites excreted in the urine of smokers and other tobacco users. Although several members of the UDP-glucuronosyltransferase (UGT) family of enzymes were previously shown to be active in catalyzing the formation of 3HC and its glucuronide, a comprehensive screening of all known humanUGT1A and 2B enzymes for glucuronidation activity against 3HC was not previously performed. METHODS: In the present study, human liver microsomes (HLM), eight UGT1A and six UGT2B enzymes were screened for activity against 3HC. RESULTS:UGT2B17 exhibited the highest O-glucuronidation activity, exhibiting a four-fold lower (P<0.005) KM (8.3 mmol/l) compared with that observed for UGTs 1A9 (35 mmol/l) or 2B7 (31 mmol/l) and a KM smaller compared with that observed for human liver microsomes (HLM; 26 mmol/l). The KM for 3HC-O-Gluc formation was 3.1-fold lower (P<0.0005) in HLM from male participants exhibiting the wild-type genotype UGT2B17 (*1/*1) compared with that in HLM from participants homozygous for the UGT2B17 deletion genotype [UGT2B17 (*2/*2)]. Both UGTs 2B10 and 1A4 exhibited 3HC-N-Gluc formation activity, with UGT2B10 exhibiting a four-fold lower (P<0.05) KM (13 mmol/l) compared with that observed for UGT1A4 (57 mmol/l) and, which was similar to the KM observed in HLM (14 mmol/l). There was 91 (P<0.0001) and 39% (P<0.001) decreases in the 3HC-N-Gluc formation activities in HLM from participants with the UGT2B10 (*2/*2) and UGT2B10 (*1/*2) genotypes, respectively, compared with that of HLM from participants with the wild-type UGT2B10 (*1/*1) genotype. CONCLUSION: These results suggest that UGT2B17 and UGT2B10 play key roles in the glucuronidation of 3HC in the human liver and that functional polymorphisms in UGT2B17 and UGT2B10 are associated with significantly reduced glucuronidation activities against 3HC.
Authors: W S Caldwell; J M Greene; G D Byrd; K M Chang; M S Uhrig; J D deBethizy; P A Crooks; B S Bhatti; R M Riggs Journal: Chem Res Toxicol Date: 1992 Mar-Apr Impact factor: 3.739
Authors: Willie Wilson; Fernando Pardo-Manuel de Villena; Beverly D Lyn-Cook; Pradeep K Chatterjee; Timothy A Bell; David A Detwiler; Rodney C Gilmore; Isis C Valladeras; Camille C Wright; David W Threadgill; Delores J Grant Journal: Genomics Date: 2004-10 Impact factor: 5.736
Authors: Douglas F Dluzen; Dongxiao Sun; Anna C Salzberg; Nate Jones; Ryan T Bushey; Gavin P Robertson; Philip Lazarus Journal: J Pharmacol Exp Ther Date: 2014-01-07 Impact factor: 4.030
Authors: Catherine A Wassenaar; David V Conti; Soma Das; Peixian Chen; Edwin H Cook; Mark J Ratain; Neal L Benowitz; Rachel F Tyndale Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-10-02 Impact factor: 4.254
Authors: Sharon E Murphy; Sung-Shim L Park; Elizabeth F Thompson; Lynne R Wilkens; Yesha Patel; Daniel O Stram; Loic Le Marchand Journal: Carcinogenesis Date: 2014-09-18 Impact factor: 4.944
Authors: Yesha M Patel; Daniel O Stram; Lynne R Wilkens; Sung-Shim L Park; Brian E Henderson; Loic Le Marchand; Christopher A Haiman; Sharon E Murphy Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-10-07 Impact factor: 4.254
Authors: Andy Z X Zhu; Lisa S Cox; Jasjit S Ahluwalia; Caroline C Renner; Dorothy K Hatsukami; Neal L Benowitz; Rachel F Tyndale Journal: Pharmacogenet Genomics Date: 2015-05 Impact factor: 2.089
Authors: Taraneh Taghavi; Christopher A Arger; Sarah H Heil; Stephen T Higgins; Rachel F Tyndale Journal: J Pharmacol Exp Ther Date: 2017-11-20 Impact factor: 4.030